Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA

BACKGROUND: Results from the phase III trial CLEOPATRA in human epidermal growth factor receptor 2-positive first-line metastatic breast cancer demonstrated significant improvements in progression-free and overall survival with pertuzumab, trastuzumab, and docetaxel over placebo, trastuzumab, and do...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Swain, S. M., Baselga, J., Miles, D., Im, Y.-H., Quah, C., Lee, L. F., Cortés, J.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2014
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4037862/
https://ncbi.nlm.nih.gov/pubmed/24685829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdu133
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars